Department of Clinical Medicine, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Giza Governorate, 112631, Egypt.
Otolaryngology Department, Hamad Medical Corporation, Doha, 3050, Qatar.
F1000Res. 2024 Jun 5;13:4. doi: 10.12688/f1000research.143321.2. eCollection 2024.
Chronic rhinosinusitis (CRS) is a condition that affects 5-12% of the general population. Endoscopic sinus surgery (ESS) is the preferred treatment because of its few adverse effects and highest success rates. The most common post-operative consequences include synechia, nasal blockage, and disease recurrence. Spray cryotherapy is a novel therapeutic approach with promising outcomes for the treatment of upper airway disorders.This review aimed to investigate the effects of spray cryotherapy (SCT) following ESS in patients with chronic rhinosinusitis.
Six electronic databases were searched for randomized clinical trials (RCTs). The selected trials were evaluated for methodological quality, and data were extracted by two independent reviewers. The Cochrane risk-of-bias tool was used to assess the quality of evidence.
Three RCTs with 85 patients were included in the final analysis. SCT was related to -16 and -77 reductions in Lund-McKay and SNOT-22 scores after 36 weeks of follow-up, in contrast to a placebo, which showed -10.4, -65. Regarding the side effects of SCT, no adverse effects were reported, and visual assessments showed no pain, visual field loss, or any other ocular complications.
SCT is a new treatment modality after endoscopic sinus surgery that shows an effective post-operative management strategy with better post-operative scales (Lund-McKay, SNOT-22, POSE, and Lund-Kennedy) and less edema, obstruction, crusting, and inflammation with minimal or no side effects. However, further research with longer follow-ups, a larger sample size, and subjective assessment is needed to assess any possible long-term side effects.
慢性鼻-鼻窦炎（CRS）影响 5%-12%的普通人群。由于其不良影响少、成功率高，内镜鼻窦手术（ESS）是首选治疗方法。最常见的术后后果包括粘连、鼻塞和疾病复发。喷雾冷冻疗法是一种治疗上呼吸道疾病的新方法，具有良好的治疗效果。本综述旨在研究 ESS 后喷雾冷冻疗法（SCT）对慢性鼻-鼻窦炎患者的影响。
在六个电子数据库中搜索随机临床试验（RCT）。对选定的试验进行方法学质量评估，并由两名独立评审员提取数据。使用 Cochrane 偏倚风险工具评估证据质量。
最终分析纳入了三项 RCTs，共 85 例患者。与安慰剂相比，SCT 在 36 周随访时，Lund-McKay 和 SNOT-22 评分分别减少了-16 和-77，而安慰剂组则减少了-10.4，-65。关于 SCT 的副作用，没有报告不良反应，视觉评估没有疼痛、视野丧失或任何其他眼部并发症。
SCT 是内镜鼻窦手术后的一种新的治疗方法，与安慰剂相比，它具有更好的术后评分（Lund-McKay、SNOT-22、POSE 和 Lund-Kennedy），水肿、阻塞、结痂和炎症更少，副作用最小或没有。然而，需要进行更长时间的随访、更大样本量和主观评估的进一步研究，以评估任何可能的长期副作用。
